Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name *
Last Name *
Email Address (Verify) *
We will request your mailing address on the next page.
We will request your mailing address on the next page.

Vidaza Received New Indication for Patients with Newly Diagnosed Juvenile Myelomonocytic Leukemia

JHOP - June 2022 Vol 12, No 3 - FDA Oncology Update
Download PDF

On May 20, 2022, the FDA accelerated the approval of a new indication for azacitidine injection (Vidaza; Celgene) for the treatment of pediatric patients with newly diagnosed juvenile myelomonocytic leukemia (JMML).

The FDA granted this indication a breakthrough therapy designation. Azacitidine injection was previously approved for the treatment of patients with myelodysplastic syndromes.

This approval was based on the results of the AZA-JMML-001 study, an international, multicenter, open-label clinical trial that evaluated the pharmacokinetics, pharmacodynamics, safety, and activity of azacitidine before hematopoietic stem-cell transplant (HSCT) in 18 pediatric patients with JMML. The patients received intravenous (IV) azacitidine on days 1 to 7 of a 28-day cycle, for a minimum of 3 cycles and a maximum of 6 cycles. Patients were included in the study if they did not have disease progression or were not ready for HSCT between cycles 4 and 6.

The main efficacy outcome measures were clinical complete remission or partial remission according to the International Juvenile Myelomonocytic Leukemia Working Group response criteria at 3 months (cycle 3, day 28). The responses must have been sustained for at least 4 weeks in the 4-week period preceding or succeeding cycle 3, or for day 28.

Of the 18 patients, 9 (50%) patients had confirmed clinical responses. Of these 9 patients, 3 patients had a complete response and 6 patients had a partial response to IV azacitidine therapy. The median time to response was 1.2 months (range, 0.95-1.87 months).

The proportion of patients undergoing HSCT was 94%, and the median time to HSCT was 4.6 months (range, 2.8-19 months).

The most common (>30%) adverse reactions reported with IV azacitidine in pediatric patients with JMML were pyrexia, rash, upper respiratory tract infection, and anemia.

The recommended dose of IV azacitidine for patients aged 1 month to <1 year or those weighing <10 kg is 2.5 mg/kg; the recommended dose for patients aged ≥1 years and weighing ≥10 kg is 75 mg/m2.

Related Items
Kymriah Received Accelerated FDA Approval for Relapsed or Refractory Follicular Lymphoma
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in FDA Oncology Update
Tibsovo Received a New Indication, in Combination with Onureg, for Newly Diagnosed Patients with AML and IDH1 Mutation
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in FDA Oncology Update
Enhertu Received Regular FDA Approval for Patients with Unresectable or Metastatic Breast Cancer
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in FDA Oncology Update
Yescarta First CAR T-Cell Therapy FDA Approved for Large B-Cell Lymphoma
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in FDA Oncology Update
Pluvicto FDA Approved for PSMA-Positive Metastatic Prostate Cancer
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in FDA Oncology Update
Opdualag, a Novel Immunotherapy Combination, FDA Approved for Advanced Melanoma
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in FDA Oncology Update
Carvykti Second BCMA-Directed CAR T-Cell Therapy FDA Approved for Multiple Myeloma
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in FDA Oncology Update
Keytruda Monotherapy FDA Approved for Endometrial Carcinoma with a Biomarker
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in FDA Oncology Update
Lynparza Receives FDA Approval for Adjuvant Treatment of High-Risk Early Breast Cancer with BRCA Mutation
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in FDA Oncology Update
Opdivo plus Platinum-Based Chemotherapy FDA Approved as First Neoadjuvant Treatment in Early-Stage NSCLC
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in FDA Oncology Update
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.